pentobarbital has been researched along with Libman-Sacks Disease in 1 studies
Pentobarbital: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236)
pentobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Drayer, DE | 1 |
| Lorenzo, B | 1 |
| Lahita, RG | 1 |
| Robbins, WC | 1 |
| Reidenberg, MM | 1 |
1 other study available for pentobarbital and Libman-Sacks Disease
| Article | Year |
|---|---|
Microsomal hydroxylation as measured by pentobarbital elimination in patients with idiopathic systemic lupus erythematosus.
Topics: Adolescent; Adult; Aged; Female; Half-Life; Humans; Hydroxylation; Kinetics; Lupus Erythematosus, Sy | 1982 |